FEDERAL COURT OF AUSTRALIA
Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5) [2024] FCA 360
File number: NSD 656 of 2017 Judgment of: NICHOLAS J Date of judgment: 12 April 2024 Catchwords: PATENTS – claims for methods of treatment and Swiss-style claims – methods of treatment for primary insomnia characterised by non-restorative sleep and for improving restorative quality of sleep – construction of claims – meaning of non-restorative sleep – meaning of characterised by non-restorative sleep – meaning of restorative quality of sleep – where fourth edition of Diagnostic and Statistical Manual of Mental Disorders (“DSM-IV”) incorporated by reference – construction of claims when read with DSM-IV – whether person skilled in the art must be familiar with DSM-IV– whether claims invalid for lack of clarity – whether invention not fully described in complete specification – whether claims invalid for lack of novelty or inventive step or fair basis – whether supply of respondents’ products constitutes an infringement under s 117(1) read with sub-sec (2)(b) or (c) of Patents Act 1990 (Cth) – whether respondents’ product is a staple commercial product – where respondents’ product capable of being used for non-infringing methods of treatment outside patented indication – whether respondents’ product information document and/or approved indication for respondents’ product constitutes a statement or inducement to use the respondents’ product so as to infringe the method of treatment claims by using it for the patented indication – whether Swiss-style claims infringed – whether respondents’ product a medicament manufactured for treating a patient suffering from primary insomnia characterised by non-restorative sleep and improving restorative quality of sleep – whether respondents authorised infringement of method of treatment claims by medical practitioners prescribing respondents’ product for patented indication – where patented indication and approved indication are different
Held: claims of patent valid, method of treatment claims infringed by supply of respondents’ product and by authorisation of medical practitioners’ infringing use of respondents’ product
Legislation: Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)
Patents Act1990 (Cth) ss 7, 13(1), 18, 40(2)(a), 40(3), 88(4), 117
Patents Amendment Act 2001 (Cth) Sch 1, Pt 1
Cases cited: Actavis UK Ltd v Janssen Pharmaceuticals NV [2008] FSR 35
Aktiebolaget Hässle v Alphapharm Pty Ltd (2002) 212 CLR 411
Allsop Inc v Bintang Ltd (1989) 15 IPR 686
Apotex Pty Limited v Sanofi-Aventis Australia Pty Limited (2013) 253 CLR 284
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 2) (2012) 204 FCR 494
Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) (2016) 122 IPR 17
AstraZeneca AB v Apotex Pty Ltd (2014) 226 FCR 324
AstraZeneca AB v ApotexPty Ltd (2015) 257 CLR 356
Atlantis Corporation Pty Ltd v Schindler (1997) 39 IPR 29
Austal Ships Pty Ltd v Stena Rederi Aktiebolag (2005) 66 IPR 420
Bristol-Myers Squibb Co v Baker Norton Pharmaceuticals Inc [1999] RPC 253
Bristol-Myers Squibb Company v Apotex Pty Ltd (No 5) (2013) 104 IPR 23
Keep reading for free
Create a free CaseChat account to read Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2024] FCA 360
- Decision Date
CaseChat Overview and Summary
The primary legal issues in the case were the validity of the patent claims, the interpretation of specific terms within the claims, and whether the respondents' product or actions constituted an infringement of the patent. The court needed to determine the meaning of terms such as "non-restorative sleep" and "restorative quality of sleep" as used in the patent claims, particularly when read in conjunction with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Additionally, the court had to decide whether the respondents' product, which could be used for non-infringing methods of treatment, infringed the patent, and whether the respondents had authorized the infringement through medical practitioners.
The court held that the claims of the patent were valid and sufficiently clear. It found that the respondents' product did infringe the method of treatment claims by being supplied and by the authorization of medical practitioners to use the product for the patented indication. The court rejected the argument that the respondents' product was a staple commercial product, which could have potentially negated the infringement. It also found that the respondents' product information document and approved indication did not constitute a statement or inducement to use the product in a manner that would infringe the patent. The court concluded that the Swiss-style claims were infringed as the respondents' product was a medicament used for treating primary insomnia characterized by non-restorative sleep and improving restorative quality of sleep. The court found that the respondents had authorized the infringement of the method of treatment claims by medical practitioners prescribing their product for the patented indication, even though the patented and approved indications differed.
The court ordered the parties to provide proposed short minutes of order and to notify the court of any disagreements regarding the scope of the orders. The proceeding was stand over for further orders.
Orders
Orders of the court
1. By 4.00pm 26 April 2024 the parties provide proposed short minutes of order to the Associate to Nicholas J in accordance with his Honour’s reasons published today.
2. By 4.00pm 26 April 2024 the parties provide to the Associate to Nicholas J written notice of the scope of any disagreement between them in relation those parts of the short minutes of order referred to in order 1 that are not agreed.
3. The proceeding stand over to 9.30am on 2 May 2024 for the making of further orders.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi